Status:
RECRUITING
DNA Methylation Combined With Artificial Intelligence Imaging to Identify Lung Nodules
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Lung Cancer Diagnosis
Eligibility:
All Genders
20-80 years
Brief Summary
Lung cancer is the leading cause of cancer deaths,and the key to reducing mortality in lung cancer patients is early diagnosis and treatment.Currently,peripheral blood DNA methylation is a novel in vi...
Eligibility Criteria
Inclusion
- (1) Patients with pulmonary nodules diagnosed by imaging;
- (2) No contraindications to blood collection;
- (3) Voluntary completed DNA methylation testing;
- (4) Signed informed consent and performed all the study mandated procedures.
Exclusion
- (1) Pregnant or lactating(6 months) women;
- (2) History of malignancy or known malignancy or precancerous lesions or known tuberculosis within 3 years;
- (3) Autoimmune system disorders;
- (4) Undergoing any diagnostic puncture therapy, such as percutaneous lung biopsy, transbronchial, pre-enrollment biopsy, or surgical procedures (within 6 months); (5) Recipients of organ transplants or prior non-autologous (allogeneic) bone marrow transplants or stem cell transplants; (6) Received antibiotic therapy within 14 days or applied a drug that elevates white blood cells within 45 days prior to the blood draw.
Key Trial Info
Start Date :
December 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06220305
Start Date
December 1 2022
End Date
December 31 2024
Last Update
January 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangsu Province Hospital
Nanjing, Jiangsu, China, 210029